tiprankstipranks
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
US Market
MAZE
Maze Therapeutics, Inc.
RESEARCH TOOLSreports

Maze Therapeutics, Inc. (MAZE) Stock News & Sentiment

78 Followers
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
Premium
Ratings
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
6d ago
MAZE
Maze Therapeutics adds Neil Kumar to board leadership
Premium
Company Announcements
Maze Therapeutics adds Neil Kumar to board leadership
7d ago
8K
MAZE
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
Premium
Ratings
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
23d ago
MAZE
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
Premium
Ratings
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
27d ago
MAZE
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst
Premium
Ratings
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst
1M ago
MAZE
Maze Therapeutics Secures New $200 Million Loan Facility
Premium
Company Announcements
Maze Therapeutics Secures New $200 Million Loan Facility
2M ago
8K
MAZE
Buy Rating on Maze Therapeutics: Attractive Risk‑Reward Driven by Differentiated APOL1 Kidney Disease Therapy MZE829 and Raised $46 Target
Premium
Ratings
Buy Rating on Maze Therapeutics: Attractive Risk‑Reward Driven by Differentiated APOL1 Kidney Disease Therapy MZE829 and Raised $46 Target
2M ago
MAZE
More MAZE News >

MAZE News on the Web

J.P. Morgan Sticks to Its Buy Rating for Maze Therapeutics, Inc. (MAZE)
TipRanks News
Neutral
Maze Therapeutics price target raised to $58 from $52 at JPMorgan
TipRanks News
Bullish
Maze Therapeutics, Inc. (MAZE) Gets a Buy from Mizuho Securities
TipRanks News
Bearish
Maze Therapeutics, Inc. (MAZE) Gets a Buy from LifeSci Capital
TipRanks News
Neutral
Weekly Buzz: CORT Wins FDA Nod In Cancer; MRK Acquires TERN; INSM Meets Trial Goals But VALN Misses
rttnews
Bullish
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
Zacks
Bullish
Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (MAZE), Azitra Inc (AZTR) and Arrowhead Pharmaceuticals (ARWR)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Maze Therapeutics, Inc. (MAZE) and Compass Therapeutics (CMPX)
TipRanks News
Bullish

News Score - Last 7 Days

Positive
MAZE
Sector Average
Media Buzz
This Week32 articles
Weekly Average12 articles
News Sentiment
This Week74%
Sector Average67%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MAZE’s Media Buzz Sentiment?
32 articles about MAZE were published this week. In an average week, 12 articles are published.
    What is MAZE’s weekly average amount of articles?
    In an average week, 12 articles about MAZE are published.
      What is MAZE’s News Sentiment?
      74% of articles about MAZE were positive this week, compared to its sector average of 67%.
        Healthcare Stocks that are Trending in the News
        PALIPalisade Bio
        640China Resources Pharmaceutical Group Ltd.
        KODKodiak Sciences
        WXIBFWuxi Biologics (Cayman)
        ITRMIterum Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week